BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17244277)

  • 1. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
    Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
    BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting.
    Berge V; Thompson T; Blackman D
    Scand J Urol Nephrol; 2007; 41(3):198-203. PubMed ID: 17469027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
    Izawa JI; Lega I; Downey D; Chin JL; Luke PP
    BJU Int; 2005 Aug; 96(3):320-3. PubMed ID: 16042722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy before radical prostatectomy is associated with poorer postoperative erectile function outcomes.
    Mazzola CR; Deveci S; Heck M; Mulhall JP
    BJU Int; 2012 Jul; 110(1):112-6. PubMed ID: 22093870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of concurrent prostate cancer in cystoprostatectomy specimens is related to volume of high-grade prostatic intraepithelial neoplasia.
    Wiley EL; Davidson P; McIntire DD; Sagalowsky AI
    Urology; 1997 May; 49(5):692-6. PubMed ID: 9145972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?
    Berthelet E; Pickles T; Truong PT; Liu M; Pai HH; Kwan WB; Lim JT;
    Can J Urol; 2007 Aug; 14(4):3621-7. PubMed ID: 17784982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy for precancerous lesions of the prostate.
    Hull D; Bostwick DG
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.
    Hara N; Nishiyama T; Takizawa I; Saito T; Kitamura Y; Takahashi K
    Urology; 2010 Jun; 75(6):1441-5. PubMed ID: 20110105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.